Immunosuppressive Agents in the Treatment of Membranoproliferative Glomerulonephritis

Abstract

INTRODUCTION: Treatment of membranoproliferative glomerulonephritis (MPGN) is often unrewarding with approximately 60% of patients progressing to end-stage renal failure within 10 years. In our study, we compared the efficacy of CS alone versus low dose CS + another immunosuppressive agent retrospectively. MATERIAL and